Alexa, What is Eliquis and Xarelto?

Patient Satisfaction Clinical Trial

Official title:

Alexa, What is Eliquis and Xarelto?

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04790773
• Other study ID #: STUDY00001194
• Status: Terminated
• Phase: N/A
• Start date: May 21, 2021
• Est. completion date: October 31, 2021

Study information

• Verified date: March 2022
• Source: Cedars-Sinai Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness of providing patient medication education about Eliquis and Xarelto through an Amazon Alexa based voice recording.

Description:

Anticoagulants are considered high-risk medications due to the risk of major bleeding. The Federal Drug and Food Administration (FDA) MedWatch reporting system found that anticoagulants had the most adverse drug event (ADE) reports in 2011. Anticoagulants have also been reported as one of the leading drug classes contributing to emergency department visits3. Given the potential for serious adverse events, providing effective education to increase patient knowledge and awareness of those risks are essential. Incorporating technology into health care is becoming increasingly popular and has been shown to be effective for patient education. One reason is that technology can consistently provide complete patient education and is not subject to educator variability in providing this education.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 36
• Est. completion date: October 31, 2021
• Est. primary completion date: June 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria (Patients):

• 18 years of age or older
• Have been prescribed either apixaban or rivaroxaban during their inpatient stay
• Consent to participating in the study

Inclusion Criteria (Nurses):

• Providing direct patient care in select general medicine and orthopedic surgical units
• Consent to participating in the study

Exclusion Criteria:

• Patients will be excluded if they have documented altered mental status, do not speak English, or are being prescribed rivaroxaban or apixaban on discharge only.
• Nurses will be excluded if not providing direct patient care in select general medicine and orthopedic surgical units
• Nurses declining participation

Related Conditions & MeSH terms

• Patient Engagement
• Patient Satisfaction

Intervention

Other:
• Amazon Alexa based voice recording patient education
Amazon Alexa based voice recording of medication education material

Locations

Country	Name	City	State
United States	Cedars Sinai Medical Center	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
Cedars-Sinai Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	% Change in pre- and post test scores	Effectiveness of Alexa based education by assessing understanding of Eliquis and Xarelto pre and post Alexa education	Within 72 hours of education
Secondary	7-day post-education retention rate	Assess education retention rate 7-days after initial Alexa based education performed	1 week post discharge
Secondary	Nursing satisfaction	Nursing satisfaction assessed by likert type scale questionnaire; How satisfied are you with the Alexa anticoagulation education process compared to standard of care? Responses: Very dissatisfied - Dissatisfied - Neutral - Satisfied - Very Satisfied; Do you agree or disagree that Alexa helps with your day-to-day workload? Responses: Strongly Agree - Agree - Neutral - Disagree - Strongly disagree	72 hours
Secondary	Patient satisfaction	Patient satisfaction assessed by likert type scale questionnaire; How satisfied are you with the anticoagulant education provided by Alexa? Responses: Very dissatisfied - Dissatisfied - Neutral - Satisfied - Very Satisfied; How strongly would you recommend using Alexa anticoagulant education to your friends, family and/or other patients? Responses: Highly recommend - Recommend - Neutral - Do not recommend	72 hours